Addex Therapeutics’ drug candidate GABAB PAM shows solid anti-tussive activity in bleomycin IPF-related chronic cough model: Geneva, Switzerland Saturday, May 2, 2026, 18:00 Hrs ...
GABAB PAM chronic cough candidate continued towards clinic after demonstrating robust anti-tussive activity in multiple disease modelsContinued ...
Please provide your email address to receive an email when new articles are posted on . Change from baseline in gait variability did not differ between groups, regardless of cognitive load. Treatment ...
Geneva, Switzerland, May 12, 2025-Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for ...
Addex Therapeutics’ GABAB PAM candidate shows robust anti-tussive activity in non-human primate chronic cough model: Geneva, Switzerland Wednesday, April 22, 2026, 18:00 Hrs [IS ...
Draig Therapeutics, a clinical-stage biopharmaceutical company developing transformative, best-in-class neuropsychiatric ...
Geneva, Switzerland, February 3, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric ...
Neuphoria’s social anxiety disorder program will be discontinued based on the results from the AFFIRM-1 trial. Topline results were announced from a phase 3 trial evaluating BNC210 in patients with ...
Dysregulation of cholinergic neurotransmission through muscarinic receptors, particularly the M1 and M4 subtypes, has been implicated in the pathophysiology of schizophrenia. Muscarinic M4 receptor ...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results